Clinical Trial News and Research

RSS

Scientists to combine NK cell therapy with immunocytokine to target childhood cancer

Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies. Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors.

11 Oct 2013

Important information on effects, side effects of drugs is missing in most publications, says study

In 2012 researchers from the German Institute for Quality and Efficiency in Health Care (IQWiG) presented a study in the BMJ analysing information sources used in 16 health technology assessment (HTA) reports of drugs ("benefit assessments").

11 Oct 2013

Computer training for Parkinson’s patients improves driving performance marker

A self-administered, nonpharmalogic intervention significantly improves the useful field of view (UFOV) of patients with Parkinson’s disease, shows a randomized trial.

10 Oct 2013

Drugs often fail to bring acromegaly under control in routine clinical practice

Over a quarter of UK patients treated for growth hormone-producing tumours do not achieve 'safe' growth hormone levels, according to a 30 year UK multi-centre study of clinical management of the rare disease acromegaly. The findings by the Society for Endocrinology UK Acromegaly Register, published in the November issue of Clinical Endocrinology, show that drugs to control acromegaly often fail to bring the disease completely under control in routine clinical practice.

10 Oct 2013

Bluhm Institute enrolls first patient in SALUS trial to evaluate movable, non-metallic heart valve

Northwestern's Bluhm Cardiovascular Institute has enrolled its first participant in SALUS, a clinical trial studying the effectiveness of a prosthetic aortic heart valve that can be placed without open-heart surgery.

10 Oct 2013

Auckland physician performs first patient implant of Boston Scientific Innova DES System

Launching a key clinical trial expected to serve as the foundation for global regulatory approvals, a physician in Auckland, New Zealand has performed the first patient implant of the Boston Scientific Corporation Innova Drug-Eluting Stent System.

10 Oct 2013

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Pfizer Inc. announced today top-line results from two Phase 3 clinical trials of tofacitinib, a novel, oral Janus kinase inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A3921111).

10 Oct 2013

Adempas drug gets FDA approval for treatment of pulmonary hypertension

The U.S. Food and Drug Administration today approved Adempas (riociguat) to treat adults with two forms of pulmonary hypertension. Pulmonary hypertension is caused by abnormally high blood pressure in the arteries of the lungs.

10 Oct 2013

TSRI scientists identify set of compounds to treat multiple sclerosis in new way

Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.

10 Oct 2013

FDA approves Phase II trial to study effect of injected stem cells in ALS patients

Two patients with amyotrophic lateral sclerosis (ALS) have received stem cell injections to their spinal cords at the University of Michigan Health System - the first two to receive the experimental injections in Michigan as part of a national clinical trial.

10 Oct 2013

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis.

10 Oct 2013

High bipolar medication adherence not elusive

Researchers have found “remarkably” high medication adherence rates among patients with bipolar disorder participating in a comparative effectiveness trial.

9 Oct 2013

U.S. Research Will "Pay Dearly" For Shutdown, ASCB Warns

...

9 Oct 2013

Alkermes announces plans to advance ALKS 5461 phase 3 program for major depressive disorder

Alkermes plc today announced that it has successfully completed its End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), and the company plans to advance ALKS 5461 into phase 3 development in early 2014.

9 Oct 2013

New method for improving cord blood transplant success

Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation.

9 Oct 2013

NeuroVigil opens satellite research lab at NASA to develop assistive technologies for ALS

NeuroVigil, Inc. is setting to collaborate with a number of partners in the Silicon Valley where it is opening a satellite research laboratory at NASA Research Park in Mountain View, CA, to develop assistive technologies for individuals suffering from ALS and other conditions affecting the central nervous system.

9 Oct 2013

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

Alkermes completes patient enrollment in phase 3 study of aripiprazole lauroxil in schizophrenia patients

Alkermes plc (NASDAQ: ALKS) today announced completion of patient enrollment in the pivotal, multinational phase 3 study evaluating aripiprazole lauroxil in patients with schizophrenia.

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the second clinical trial of Glial Growth Factor 2 (GGF2). This Phase 1b single-infusion trial in people with heart failure will assess tolerability of three dose levels of GGF2, and also includes several explorative measures of efficacy.

9 Oct 2013

Clinical Trial News and Research

Scientists to combine NK cell therapy with immunocytokine to target childhood cancer

Important information on effects, side effects of drugs is missing in most publications, says study

Computer training for Parkinson’s patients improves driving performance marker

Drugs often fail to bring acromegaly under control in routine clinical practice

Bluhm Institute enrolls first patient in SALUS trial to evaluate movable, non-metallic heart valve

Auckland physician performs first patient implant of Boston Scientific Innova DES System

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Adempas drug gets FDA approval for treatment of pulmonary hypertension

TSRI scientists identify set of compounds to treat multiple sclerosis in new way

FDA approves Phase II trial to study effect of injected stem cells in ALS patients

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

High bipolar medication adherence not elusive

U.S. Research Will "Pay Dearly" For Shutdown, ASCB Warns

Alkermes announces plans to advance ALKS 5461 phase 3 program for major depressive disorder

New method for improving cord blood transplant success

NeuroVigil opens satellite research lab at NASA to develop assistive technologies for ALS

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Alkermes completes patient enrollment in phase 3 study of aripiprazole lauroxil in schizophrenia patients

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer